New Analysis Highlights Urgent Need for Alzheimer’s Disease Drug Development

Even with an estimated 44 million people living with Alzheimer s disease (AD), relatively few new AD drugs are in development. Additionally, the failure rate for AD drug development is 99.6 percent from the years 2002 to 2012 and the number of AD drugs has been declining since 2009. In a new analysis published today, researchers say there is an urgent need to increase the number of agents entering the AD drug development pipeline.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy